The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | Treatment approaches for fit and frail multiple myeloma patients
Jesus San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the different treatment approaches for fit and frail patients. For patients that are fit and active, regardless of whether they are transplant eligible or not, treatment should be as soon as possible and aimed to eradicate all the disease. For older, frail patients, treatment should be aimed to be convenient, improve quality of life and offer the best palliative care. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Consulting or Advisory role for Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, GSK, Abbvie and Karyopharm.
